Quoin Pharmaceuticals gets FDA Fast Track for QRX003
Quoin Pharmaceuticals said the FDA granted Fast Track designation for QRX003 in Peeling Skin Syndrome. The company said it is preparing a Phase 2/3 study in 2H 2026.
Quoin Pharmaceuticals said the FDA granted Fast Track designation for QRX003 in Peeling Skin Syndrome. The company said it is preparing a Phase 2/3 study in 2H 2026.